section name header

Evidence summaries

Antipsychotics for Delirium

Haloperidol in low dosage may have similar efficacy as the atypical antipsychotics olanzapine and risperidone in the management of delirium. It may have slightly greater frequency of adverse drug effects than these drugs. Level of evidence: "C"

A Cochrane review [Abstract] 1 included 3 studies with a total of 629 subjects. These studies compared haloperidol with risperidone, olanzapine, and placebo in the management of delirium and in the incidence of adverse drug reactions. Decrease in delirium scores were not significantly different comparing the effect of low dose haloperidol (< 3.0 mg per day) with the atypical antipsychotics olanzapine and risperidone (Odds ratio 0.63 (95% CI 10.29 - 1.38; p = 0.25). Low dose haloperidol did not have a higher incidence of adverse effects than the atypical antipsychotics. High dose haloperidol (> 4.5 mg per day) in one study was associated with an increased incidence of extrapyramidal adverse effects, compared with olanzapine. Low dose haloperidol decreased the severity and duration of delirium in post-operative patients, although not the incidence of delirium, compared to placebo controls in one study. There were no controlled trials comparing quetiapine with haloperidol.

Comment: The quality of evidence is downgraded by imprecise results (limited study size for each comparison) and indirectness (differences in studied patients).

References

  • Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev 2007 Apr 18;(2):CD005594. [PubMed]

Primary/Secondary Keywords